1. Home
  2. MDWD vs SHMD Comparison

MDWD vs SHMD Comparison

Compare MDWD & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • SHMD
  • Stock Information
  • Founded
  • MDWD 2000
  • SHMD 1864
  • Country
  • MDWD Israel
  • SHMD Germany
  • Employees
  • MDWD N/A
  • SHMD N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • SHMD
  • Sector
  • MDWD Health Care
  • SHMD
  • Exchange
  • MDWD Nasdaq
  • SHMD Nasdaq
  • Market Cap
  • MDWD 179.1M
  • SHMD 171.9M
  • IPO Year
  • MDWD 2014
  • SHMD N/A
  • Fundamental
  • Price
  • MDWD $18.06
  • SHMD $3.63
  • Analyst Decision
  • MDWD Strong Buy
  • SHMD
  • Analyst Count
  • MDWD 1
  • SHMD 0
  • Target Price
  • MDWD $28.00
  • SHMD N/A
  • AVG Volume (30 Days)
  • MDWD 52.9K
  • SHMD 25.8K
  • Earning Date
  • MDWD 08-14-2024
  • SHMD 09-24-2024
  • Dividend Yield
  • MDWD N/A
  • SHMD N/A
  • EPS Growth
  • MDWD N/A
  • SHMD N/A
  • EPS
  • MDWD N/A
  • SHMD N/A
  • Revenue
  • MDWD $20,141,000.00
  • SHMD N/A
  • Revenue This Year
  • MDWD $30.16
  • SHMD N/A
  • Revenue Next Year
  • MDWD $18.44
  • SHMD N/A
  • P/E Ratio
  • MDWD N/A
  • SHMD N/A
  • Revenue Growth
  • MDWD N/A
  • SHMD 79.48
  • 52 Week Low
  • MDWD $7.45
  • SHMD $2.69
  • 52 Week High
  • MDWD $24.00
  • SHMD $6.13
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 51.78
  • SHMD N/A
  • Support Level
  • MDWD $16.25
  • SHMD N/A
  • Resistance Level
  • MDWD $17.90
  • SHMD N/A
  • Average True Range (ATR)
  • MDWD 1.02
  • SHMD 0.00
  • MACD
  • MDWD 0.00
  • SHMD 0.00
  • Stochastic Oscillator
  • MDWD 42.09
  • SHMD 0.00

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

Share on Social Networks: